Cellfina CK1-EU Rev ARecalls & reported problems
Ulthera, Inc. · Class 2
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 3
- Deaths reported
- 0
- Injuries reported
- 1
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 3 adverse event reports that list this exact device (DI 00840763100537), received between Mar 2, 2017 and Jun 26, 2018 — classified as 1 injury, 2 malfunctions.
The most frequently reported specific device problem is “Break” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem1
- Appropriate Device Problem Term/Code Not Available1
- Break1
- Physical Property Issue1
Patient problems
- Device Embedded In Tissue or Plaque1
- Laceration(s)1
- No Known Impact Or Consequence To Patient1
Recent adverse event reports
The 3 most recent of 3 reports, in the reporter's own words as published by the FDA.
MalfunctionJun 26, 2018Break; Break
A (B)(6) AFFILIATE FROM (B)(6) RECEIVED A REPORT ON (B)(6) 2018 REGARDING A CELLFINA BLADE. IT WAS REPORTED THAT AFTER 25 RELEASES, THE BLADE BROKE. THE AFFILIATE STATED THAT THERE WERE NO DISADVANTAGES FOR THE PATIENT.
Patient problems: No Known Impact Or Consequence To Patient
MAUDE report 7640073 ↗MalfunctionMar 26, 2018Physical Property Issue; Appropriate Device Problem Term/Code Not Available; Physical Property Issue; Appropriate Device Problem Term/Code Not Available
ON (B)(6) 2018, THE MERZ AFFILIATE IN (B)(4) WAS MADE AWARE OF A PRODUCT PROBLEM THAT OCCURRED IN (B)(6). IT WAS REPORTED THAT THE BLADE FROM A CELLFINA DISPOSABLE KIT BROKE DURING A TREATMENT REQUIRING RETRIEVAL. NO ADDITIONAL LOCAL ANAESTHETIC WAS ADMINISTERED NOR WERE SUTURES REQUIRED TO CLOSE THE RETRIEVAL POINT.
Patient problems: Device Embedded In Tissue or Plaque
MAUDE report 7370565 ↗InjuryMar 2, 2017Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
DURING A CELLFINA PROCEDURE, THE PHYSICIAN HAD TO INCREASE THE PRESSURE OF THE VACUUM IN ORDER TO HAVE A GOOD VACUUM ASSISTED TISSUE CAPTURE USING THE VACUUM HANDPIECE. DURING A SUBCUTANEOUS TISSUE RELEASE WITH THE MOTOR MODULE SWITCHED ON, THE VACUUM PRESSURE WAS LOST, RESULTING IN A 2-3 CM LACERATION OF THE PATIENTS SKIN. THE PHYSICIAN SPECULATES THE IMMEDIATE VACUUM PRESSURE LOSS WAS DUE TO: NUMEROUS STABS THROUGH THE ELASTOMERIC SEPTUM OF THE VACUUM HANDPIECE MAY HAD CAUSED A HOLE/DISRUPTION IN THE SEPTUM THAT LET AIR THROUGH; SKIN SURFACE TOO WET; ACCIDENTAL SWITCHING OFF OF THE VACUUM FOOT PEDAL. THE PHYSICIAN STATED THAT PERSON OPERATING THE VACUUM FOOT PEDAL WAS NOT A MEDICAL PROFESSIONAL, AND MAY HAVE BUMPED THE PEDAL.
Patient problems: Laceration(s)
MAUDE report 6374664 ↗
Other Powered Surgical Instrument For Improvement In The Appearance Of Cellulite devices
- Cellfina System Disposable Procedure Kit Rev OUlthera, Inc. · Powered Surgical Instrument For Improvement In The Appearance Of Cellulite4 reports
- Cellfina Motor Module Device and Package CM1 Rev C, D, EUlthera, Inc. · Powered Surgical Instrument For Improvement In The Appearance Of Cellulite1 report
- Cellfina System Disposable Tray CK1 Rev JUlthera, Inc. · Powered Surgical Instrument For Improvement In The Appearance Of Cellulite1 report
- Cellfina System Disposable Tray CK1 Rev KUlthera, Inc. · Powered Surgical Instrument For Improvement In The Appearance Of Cellulite1 report
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page